Viking Therapeutics, Inc.
VKTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.63 | -6.00 | -0.42 | -0.16 |
| FCF Yield | -2.00% | -4.18% | -6.70% | -13.40% |
| EV / EBITDA | -39.83 | -16.88 | -9.77 | -5.94 |
| Quality | ||||
| ROIC | -17.12% | -28.83% | -46.77% | -27.08% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.85 | 0.70 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.64% | -51.61% | -1.70% | -118.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 0.54 | 0.50 | 0.48 |
| Interest Coverage | -1,605.54 | -1,145.76 | 0.00 | -3,093.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -10,351.86 | -9,390.00 | -10,697.89 | -1,780.61 |